TitAIN Trial Provides Hope to Giant Cell Arteritis Patients
A recent phase 2 safety and efficacy study of an anti-interleukin-17A monoclonal antibody for the treatment of giant cell arteritis patients suggests there may soon be another alternative to ...
Steroid-toxicity should, and can now be, measured in routine clinical practice
Glucocorticoids have saved countless lives since being discovered 75 years ago. Yet, long-term exposure is associated with a range of toxicities including an increased risk of devastating adverse ...
In Conversation With… Wen Zhang, MD PhD
“We have a saying in China, ‘to turn pale at the mention of a tiger’, and this describes the fear many patients show when told they need to be prescribed steroids.” Wen Zhang, MD PhD is a Professor ...
Highlights from EULAR 2023
Milan played host to EULAR 2023, the European Congress of Rheumatology May 31st to June 3rd and featured an engaging scientific program and lots of stimulating conversations and meetings. John H. ...
In Conversation With… David Jayne, MD
“I think we have a real problem in how we deliver steroid reduction, and that in part is due to the complexity of constantly changing doses.” David Jayne, MD is a clinical nephrologist at ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
